exa-cel
Vertex pharmaceuticals,CRISPR therapeutics AG
[]
 at the #eha2022 congress, leo kager (head of ) commented on our own data and on one of his personal congress highlights the first-in-human crispr-cas-treatment of #sicklecelldisease and #thalassemia major. 
CCRI is developing and optimizing diagnostic, prognostic and therapeutic strategies for the treatment of children suffering from cancer.